Angiotech On Track To Building Drug-Loaded Device Franchise – CEO Hunter
This article was originally published in The Gray Sheet
Executive Summary
Angiotech's combination product pipeline includes drug-loaded versions of the CoSeal surgical sealant, CoStasis surgical hemostat and Adhibit adhesion barrier, CEO William Hunter stated in an Aug. 17 earnings call
You may also be interested in...
Angiotech Vascular Wrap Will Bring Paclitaxel To Vascular Surgeons
Angiotech will begin clinical trials in late 2003 on its paclitaxel-eluting Vascular Wrap for prevention of restenosis following leg artery bypass surgery
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.